NASDAQ · LBRX
LB Pharmaceuticals Inc Common Stock
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
Loading market information…
NASDAQ · KRRO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Korro Bio, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$1.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Korro Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$2.49+4.23% vs estimate | $2.55M+497.33% vs estimate |
|---|
| Q4 2024 | Mar 18, 2025 | -$2.26+3.0% vs estimate | $2.27M |
|---|
| Q3 2024 | Nov 12, 2024 | -$2.26+11.37% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $15.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$6.30-$0.11 (-1.64%)
Aura Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.01% below the high.
$2.14+$0.04 (+1.9%)
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
$12.74-$0.01 (-0.08%)
Amarin Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 26.43% below the high.
